Trial Profile

A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Dec 2025 According to a Sarah Cannon Research Institute media, company will showcase data from this study at the 67thAmerican Society of Hematology (ASH) Annual Meeting & Exposition, taking place in Orlando, Florida and virtually from December 6-9.
25 Nov 2025 According to a Novartis media release, data from the trial will be presented at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition and 2025 San Antonio Breast Cancer Symposium
29 May 2025 According to a Sarah Cannon Research Institute media release, interim analysis form this trial will be presented at the ASCO 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com